Improved outcome in adult acute myeloid leukemia is almost entirely restricted to young patients and associated with stem cell transplantation

European Journal of Haematology

Volumn 68, Issue 1, 2002, Pages 54-63

  Wahlin, Anders ^a,b   Markevärn, Berit ^a   Golovleva, Irina ^a   Nilsson, Marie ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acute myeloid leukemia; Age; Allogeneic transplant; Autologous transplant; Cytogenetics; Survival

Indexed keywords

AMSACRINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; IDARUBICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; AGED; ALLOTRANSPLANTATION; ARTICLE; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CYTOGENETICS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA;

ACUTE DISEASE; ADOLESCENT; ADULT; AGE FACTORS; AGED; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID; LIFE TABLES; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; SALVAGE THERAPY; SURVIVAL ANALYSIS; SURVIVAL RATE; SWEDEN; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0036113544     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2002.00562.x     Document Type: Article

References (20)

1. Acute myeloid leukemia
2. Intensive postremission chemotherapy in adults with acute myeloid leukemia
3. Underrepresentation of patients 65 years of age or older in cancer-treatment trials
4. Prognostic significance of karyotype in de novo adult acute myeloid leukemia
5. Incidence of chromosome abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia
6. Chromosomal abnormalities in 478 children with acute myeloid leukemia: Clinical characteristics and treatment outcome in a cooperative pediatric oncology group study POG 8821
7. The clinical significance of karyotype in acute myelogenous leukemia
8. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype
9. Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-American-British Cooperative Group
10. Proposals for the classification of the myelodysplastic syndromes
11. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen
12. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
13. Regression models and life tables
14. Statistical aspects of the analysis of data from retrospective studies of disease
15. Haematologists' approaches to the management of adolescents and young adults with acute leukaemia
16. AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: Results from the MRC's 9th trial
17. Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia
18. The importance of diagnostic cytogenetics on outcome in AML analysis of 1612 patients entered into the MRC AML 10 trial
19. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDRI) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study
20. Acute myeloid leukemia